Sequence-Based Disclosure in Biotechnology

In biotechnology, nucleotide and amino acid sequences provide the most precise and widely accepted means of defining genes, proteins, and microorganisms. These sequences are analogous to chemical formulas in chemistry. As a result, sequence information plays a central role in satisfying the disclosure requirements of patent law.

Sequences are entered into applications in the form of a “Sequence Listing,” which assigns each individual nucleotide or amino acid sequence a unique identification number. These numbers are often used in claims, and the sequences themselves are frequently used in patentability and freedom-to-operate searches.

For genes, peptides, and proteins, complete sequence information provides strong support for a narrow claim to an exact molecule. However, additional information may still be needed, particularly where the molecule is long, complex, post-translationally modified, requires a particular conformation, or is claimed by function, activity, fragments, variants, or percent identity. In all cases, the application must satisfy the requirement of explaining how the claimed subject matter can be made and used.

As discussed in a previous Snapshot, a properly identified biological deposit can help satisfy the written description and enablement requirements for a microorganism, cell line, plasmid-containing host cell, or other reproducible biological material. However, this is ordinarily not sufficient by itself. The specification should also include enough information to specifically identify the deposited material, permit examination, verify that the deposit corresponds to the disclosed material, and assist in resolving infringement issues. Partial or full sequence information can help significantly in this regard.

Sequence-based disclosure also has important implications for claim scope. Claims that are limited to a specific disclosed sequence are generally more likely to be supported, but they may also offer only relatively narrow protection. Broader claims, such as those encompassing variants, homologs, or sequences defined by a level of percent identity, raise more significant issues. In such cases, the specification must provide sufficient guidance to justify the claimed breadth, including an explanation of variations that are expected to retain relevant functions.

These issues illustrate a fundamental challenge in biotechnology: the tension between defining an invention with precision and claiming it broadly enough to provide meaningful protection. Sequences provide a precise definition of a particular embodiment, but they do not, by themselves, support a wide range of variants. As a result, the relationship between sequence disclosure and claim scope is often a central point of analysis in biotechnology patent applications.

The role of sequences in biotechnology stands in contrast to chemistry, where compounds are typically defined by structural formulas that inherently capture permissible variation through well-understood substituent relationships. In biotechnology, by contrast, even small changes in sequence may lead to significant and unpredictable changes in function. This difference reinforces the need for detailed and carefully considered disclosure when sequences are used to define an invention.

Disclaimer: This piece is provided for general informational purposes only and does not constitute legal advice. Patent issues are often complex and highly fact-specific, and no one should act on general information of this kind without consulting qualified patent counsel regarding the particular circumstances involved.